Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 9Active not recruiting 4Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Refractory or Relapsed Solid Tumors 1Non-metastatic Castration-resistant Prostate Cancer 1

Interventions

Specimen Handling 21Magnetic Resonance Spectroscopy 17Carboplatin 16Gemcitabine 14pembrolizumab 11Paclitaxel 11Cisplatin 11Interviews as Topic 10Injections 10fludarabine 9Radiotherapy 8Oxaliplatin 8Nivolumab 8Dexamethasone 8Cyclophosphamide 8Irinotecan 7Fluorouracil 7Bortezomib 7Biopsy 7Bevacizumab 7toripalimab 6Radiosurgery 5Pemetrexed 5Leucovorin 5Capecitabine 5130-nm albumin-bound paclitaxel 5trastuzumab deruxtecan 4liposomal doxorubicin 4cemiplimab 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × darolutamide × 30 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡